Helen Sabzevari, PhD, President and CEO of Precigen, presented a corporate and clinical overview.

Helen Sabzevari, PhD, President and CEO of Precigen, participated in a panel discussion hosted by Scott Gottlieb, MD, on Precision Medicine - The importance of biomarkers and cytogenetic profiling in drug discovery, development and commercialization.

Precigen hosted a virtual event to provide an update on the latest progress for its clinical pipeline. The event showcased data from several of the Company’s most advanced clinical programs, such as PRGN-3005 UltraCAR-T®, PRGN-3006 UltraCAR-T® and AG019 ActoBiotics^TM.

Tim Chan, PhD, Senior Director, Immuno-Oncology of Precigen presented the poster “PRGN-3005 UltraCAR-T™: Multigenic CAR-T Cells Generated Using Non-viral Gene Delivery and Rapid Manufacturing Process for the Treatment of Ovarian Cancer”. (Abstract 6593)

Precigen held a virtual meeting for the 2020 Annual Meeting of Shareholders.

Helen Sabzevari, PhD, President and CEO of Precigen, presented Precigen’s progress to date and a 2020 look ahead.

Tim Chan, PhD, Senior Director, Immuno-Oncology of Precigen presented the poster “Preclinical Characterization of PRGN-3006 UltraCAR-T™ for the Treatment of AML and MDS: Non-Viral, Multigenic Autologous CAR-T Cells Administered One Day after Gene Transfer.” (Abstract #2660)

Helen Sabzevari, PhD, President of Precigen, presented the keynote “Unleashing the potential of gene therapy using the non-viral UltraCAR-T platform for hematological and solid tumors.”

Helen Sabzevari, PhD, President of Precigen, hosted a conference call to provide Precigen business and pipeline updates.

Helen Sabzevari, PhD, President of Precigen, presented at JMP Securities Life Sciences Conference.

Helen Sabzevari, PhD, President of Precigen, presented at the 8th Annual SVB Leerink Global Healthcare Conference.